目的：系统评价雷珠单抗玻璃体腔注射联合复合式小梁切除及视网膜光凝术(PRP)与复合式小梁切除术联合PRP治疗新生血管性青光眼(NVG)的有效性和安全性。

方法：检索万方数据库、中国知网(CNKI)、PubMed、EMbase、中国生物医学文献服务系统(CBM)、Clinicalkey、Cochrane Library数据库，查找自建库至2022-07-20试验组为雷珠单抗玻璃体腔注射联合复合式小梁切除术及PRP治疗NVG，对照组为复合式小梁切除术联合PRP治疗NVG的临床研究，同时查阅相关参考文献。提取最佳矫正视力、眼压、并发症发生情况、手术成功率进行分析。

结果：本研究共纳入8篇临床研究，NVG患者864例864眼。Meta分析结果提示，试验组患者术后1wk，1、3mo时眼压较对照组下降更低(术后1wk：MD=-4.00，95%CI：-4.62～-3.38，P<0.05； 术后1mo：MD=-4.11，95%CI：-4.66～-3.56，P<0.05； 术后3mo：MD=-4.58，95%CI：-5.61～-3.55，P<0.05)； 试验组患者术后1mo时最佳矫正视力优于对照组(MD=0.17，95%CI：0.11～0.23，P<0.05)，但两组患者术后1wk时无差异(MD=0.08，95%CI：-0.13～0.29，P=0.47)； 试验组患者术后并发症发生更少(OR=0.30，95%CI：0.18～0.52，P<0.05)，手术成功率更高(OR=5.15，95%CI：2.78～9.53，P<0.05)。

结论：雷珠单抗玻璃体腔注射联合复合式小梁切除术及PRP治疗NVG可降低眼压、改善视力，手术成功率优于复合式小梁切除术联合PRP。

METHODS: Databases including Wanfang database, China National Knowledge Infrastructure(CNKI), PubMed, EMbase, China Biomedical Document Service System(CBM), Clinicalkey, and Cochrane Library were retrieved. Literatures about intravitreal ranibizumab combined with compound trabeculectomy and PRP in the treatment of NVG in the experimental group and compound trabeculectomy and PRP in the treatment of NVG in the control group from creation of database to July 20, 2022 were searched. At the same time, relevant reference were consulted. The best corrected visual acuity, intraocular pressure, occurrence of complications and the success rate of the surgery were systematically evaluated.

RESULTS: A total of 8 clinical studies were included, with 864 patients(864 eyes)with NVG. Meta-analysis showed that the intraocular pressure of patients in the experimental group was lower than that in the control group at 1wk, 1 and 3mo after surgery(1wk: MD=-4.00, 95%CI: -4.62～-3.38, P<0.05; 1mo: MD=-4.11, 95%CI: -4.66～-3.56, P<0.05; 3mo: MD=-4.58, 95%CI: -5.61～-3.55, P<0.05). The best corrected visual acuity of the experimental group was better than that of the control group at 1mo after surgery(MD=0.17, 95%CI: 0.11～0.23, P<0.05), but there was no significant difference at 1wk after surgery(MD=0.08, 95%CI: -0.13～0.29, P=0.47). The patients in the experimental group had fewer complications(OR=0.30, 95%CI: 0.18～0.52, P<0.05)and higher surgical success rate(OR=5.15, 95%CI: 2.78～9.53, P<0.05).

CONCLUSION:With decreased intraocular pressure, improved visual acuity and surgical success rate, intravitreal ranibizumab combined with compound trabeculectomy and PRP was better than the compound trabeculectomy and PRP in the treatment of NVG.